- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Lactic acidosis with hypoglycemia and hyperammonemia observed in two uremic patients during calcium calcium hopantenate treatment.
-
- OTSUKA Masakazu
- Department of Internal Medicine, Tokyo Medical and Dental University
-
- AKIBA Takashi
- Department of Internal Medicine, Tokyo Medical and Dental University
-
- OKITA Yoshiko
- Department of Internal Medicine, Tokyo Medical and Dental University
-
- TOMITA Kimio
- Department of Internal Medicine, Tokyo Medical and Dental University
-
- YOSHIYAMA Naoki
- Department of Internal Medicine, Tokyo Medical and Dental University
-
- SASAOKA Takuo
- Department of Internal Medicine, Yokosuka Mutual Hospital
-
- KANAYAMA Masaaki
- Department of Internal Medicine, Yokosuka Mutual Hospital
-
- MARUMO Fumiaki
- Department of Internal Medicine, Tokyo Medical and Dental University
Search this article
Description
Calcium hopantenate (HOPA), a drug for treating symptoms of cerebrovascular disease, is a derivative of gamma-amino butyric acid and is also an analog of pantothenic acid. It is speculated that calcium hopantenate may affect lactate generation, glucose metabolism, and ammonia disposal through the inhibition of pantothenic acid metabolism. We report two uremic patients with complaints of consciousness disturbance with lactic acidosis, hypoglycemia and hyperammonemia. HOPA is mainly excreted with urine. Severe accumulation of HOPA, documented at the onset of unconsciousness in our uremic cases, might be responsible for marked inhibition of pantothenic acid metabolism.
Journal
-
- Japanese Journal of Medicine
-
Japanese Journal of Medicine 29 (3), 324-328, 1990
The Japanese Society of Internal Medicine
